Review ArticlesGoblet Cell Carcinoid/Carcinoma: An UpdateZhang, Kuixing MD*; Meyerson, Cherise MD†; Kassardjian, Ari MD, PhD†; Westbrook, Lindsey M. MD†; Zheng, Wei MD, PhD†; Wang, Hanlin L. MD, PhD†Author Information *Department of Pathology and Laboratory Medicine, University of California at Irvine, Orange †Department of Pathology and Laboratory Medicine, University of California at Los Angeles, Los Angeles, CA The authors have no funding or conflicts of interest to disclose. Reprints: Hanlin L. Wang, MD, PhD, Department of Pathology and Laboratory Medicine, University of California at Los Angeles, 10833 Le Conte Avenue, 27-061-C8 CHS, Los Angeles, CA 90095 (e-mail: email@example.com). Advances In Anatomic Pathology: March 2019 - Volume 26 - Issue 2 - p 75-83 doi: 10.1097/PAP.0000000000000222 Buy Metrics Abstract Goblet cell carcinoid (GCC) or goblet cell carcinoma is a unique mixed endocrine-exocrine neoplasm that is almost exclusively seen in the appendix. The hallmark of GCC is the concentric infiltration of the appendiceal wall by small tight clusters, nests or cords of tumor cells that exhibit a goblet cell morphology with a small compressed nucleus and conspicuous intracytoplasmic mucin. The coexistence of high-grade adenocarcinoma with GCC has been increasingly recognized as a common finding, which has been called adenocarcinoma ex GCC or mixed GCC-adenocarcinoma. A number of studies have shown that it is the high-grade adenocarcinomatous component that dictates the prognosis. Several histologic classification/grading systems have been proposed, which correlate with overall patient survival. Treatment options are primarily based on tumor stage and the presence or absence of a high-grade adenocarcinomatous component. Copyright © 2018 Wolters Kluwer Health, Inc. All rights reserved.